机译:体内外非竞争性雄激素受体抑制
Departments of Neurology, University of California San Francisco, San Francisco, CA 94115 Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94115;
Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94115;
Biopharmaceutical Sciences, University of California San Francisco, San Francisco, CA 94115;
Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital,Memphis, TN 38105;
Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital,Memphis, TN 38105;
Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94115;
Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115;
Departments of Neurology, University of California San Francisco, San Francisco, CA 94115 Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94115 Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115;
antagonist; harmol; pyrvinium;
机译:N-烷基化右美沙芬衍生物作为α-(3)β(4)烟碱乙酰胆碱受体的非竞争性抑制剂的合成,体内外研究和分子模型
机译:4-甲基-3-氧代-4-氮杂-5α-雄烷-1-烯-17β-N-芳基-羧酰胺:一种联合雄激素阻断的方法(5α-还原酶抑制与体外雄激素受体结合)。
机译:雄激素受体氨基末端肽的异位表达导致雄激素受体功能障碍并抑制雄激素受体介导的前列腺癌的生长。
机译:在马掺杂控制的背景下,andarine新陈代谢的体外/体内研究,一种选择性雄激素受体调节剂(SARM)
机译:恢复雄激素受体表达改变了M12人前列腺癌细胞系的体外和体内行为。
机译:体内外非竞争性雄激素受体抑制
机译:体内外非竞争性雄激素受体抑制
机译:siRNa介导的雄激素受体基因沉默对前列腺癌雄激素非依赖性生长的抑制作用;最终报告2004年1月15日至2008年1月